Boston Scientific (BSX), a leading global player in medical devices, announced solid Q4 earnings but offered 2026 guidance that slightly fell short of elevated investor..

Boston Scientific (NYSE: BSX) shares have fallen sharply in recent weeks, taking the stock back to technical support levels ...

On Wednesday, Boston Scientific experienced a loss of nearly one-fifth of its market capitalization in a single trading ...

Boston Scientific Corporation (NYSE:BSX) is one of the best medical technology stocks to invest in. On February 6, RBC ...

I'll be keeping a close eye on Boston Scientific stock following the market's peculiar reaction to its solid earnings report.

Today, Feb. 4, 2026, investors are weighing Boston Scientific’s guidance against new deals and its long-term margin path.

Boston Scientific stock fell 8.4% despite beating Q4 earnings as weak Q1 guidance and electrophysiology division miss ...

Boston Scientific’s share price — which medical device competitors have long envied — sputtered Feb. 4 after the company ...

Boston Scientific has announced new data backing its Farapulse pulsed field ablation (PFA) platform for treating AFib.

Q4 2025 earnings call recap: revenue, EPS beat, 2026 organic growth & guidance, key drivers (EP, WATCHMAN) and risks—read now ...

Penumbra, which developed the Lightning Bolt 6X, to remove blood clots below the knee, is being acquired by Boston Scientific. Boston Scientific is spending $14.5 billion in cash and stock to buy ...